» Articles » PMID: 38212499

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity Against B16-F10, MC38 and Hep1-6 Tumor Models

Overview
Date 2024 Jan 11
PMID 38212499
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the anti-tumor effects of Pien Tze Huang (PZH) in mouse models of B16-F10 melanoma, MC38 colorectal cancer, Hep1-6 hepatocellular carcinoma and chemically induced hepatocellular carcinoma model.

Methods: Various tumor models, including B16-F10, MC38 and Hep1-6 tumor hypodermic inoculation models, B16-F10 and Hep1-6 pulmonary metastasis models, Hep1-6 orthotopic implantation model, and chemically induced hepatocellular carcinoma model, were utilized to evaluate the anti-tumor function of PZH. Tumor growth was assessed by measuring tumor size and weight of solid tumors isolated from C57BL/6 mice. For cell proliferation and death of tumor cells in vitro, as well as T cell activation markers, cytokine production and immune checkpoints analysis, single-cell suspensions were prepared from mouse spleen, lymph nodes, and tumors after PZH treatment.

Results: PZH demonstrated significant therapeutic efficacy in inhibiting tumor growth (P<0.01). Treatment with PZH resulted in a reduction in tumor size in subcutaneous MC38 colon adenocarcinoma and B16-F10 melanoma models, and decreased pulmonary metastasis of B16-F10 melanoma and Hep1-6 hepatoma (P<0.01). However, in vitro experiments showed that PZH only had slight impact on the cell proliferation and survival of tumor cells (P>0.05). Nevertheless, PZH exhibited a remarkable ability to enhance T cell activation and the production of interferon gamma, tumor necrosis factor alpha, and interleukin 2 in CD4 T cells in vitro (P<0.01 or P<0.05). Importantly, PZH substantially inhibited T cell exhaustion and boosted cytokine production by tumor-infiltrating CD8 T cells (P<0.01 or P<0.05).

Conclusion: This study has confirmed a novel immunomodulatory function of PZH in T cell-mediated anti-tumor immunity, indicating that PZH holds promise as a potential therapeutic agent for cancer treatment.

Citing Articles

Promise and challenges of traditional Chinese medicine, specifically , in liver cancer treatment.

Xu A, Zhao Z, Zhu L, Zhang Y, Li Y, Wei Y World J Gastroenterol. 2024; 30(40):4380-4385.

PMID: 39494098 PMC: 11525868. DOI: 10.3748/wjg.v30.i40.4380.

References
1.
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez W, Hansen A, Gouw A, Felsher D . The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2021; 19(1):23-36. PMC: 9083341. DOI: 10.1038/s41571-021-00549-2. View

2.
Kelley K, Aronowitz P . Cancer. Med Clin North Am. 2022; 106(3):411-422. DOI: 10.1016/j.mcna.2021.12.006. View

3.
Timar J, Ladanyi A . Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. Int J Mol Sci. 2022; 23(10). PMC: 9140388. DOI: 10.3390/ijms23105384. View

4.
Patel S, Minn A . Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 2018; 48(3):417-433. PMC: 6948191. DOI: 10.1016/j.immuni.2018.03.007. View

5.
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L . Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019; 25(12):1916-1927. PMC: 6898788. DOI: 10.1038/s41591-019-0654-5. View